Geratherm Medical AG
Geratherm Medical AG is a German-based company that develops, produces, and distributes medical devices and equipment, primarily focused on the healthcare services and equipment sector.
Business. Geratherm Medical AG (GMEG.DE) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Germany, the company is primarily listed on the Xetra exchange.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Geratherm Medical AG (GMEG.DE) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Germany, the company is primarily listed on the Xetra exchange.
Geratherm Medical AG has a fully diluted share count of 5,411,945 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible securities. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the valuation snapshot, making it difficult to compare with industry_config preferred metrics or cohort medians. Without disclosed revenue, EBITDA, or net income figures, a direct comparison to industry peers is not possible.
Geratherm Medical AG's revenue concentration by segment or geography is not disclosed in the available data. The company's exposure to specific markets or product lines remains unclear, limiting the ability to assess geographic or segment-level risk.
The company's growth trajectory is not quantified in the available data. Analysts have provided a mean price target of 6.00 EUR, with a median and high price target also at 6.00 EUR, suggesting a consensus on valuation but no directional guidance on revenue or earnings growth.
The company's risk profile includes a low dilution potential, as no dilutive instruments are currently outstanding. However, the absence of balance-sheet data prevents a full assessment of liquidity risk. No adjustments have been applied to valuation metrics, and no specific risk factors are disclosed in the available source documents.
No recent filings or transcripts are available in the source documents to provide insight into the company's strategic direction or operational developments. The lack of recent disclosures limits the ability to assess the company's current performance or future outlook.
- Geratherm Medical AG has no dilution from stock options or convertible securities, as basic and diluted shares are equal.
- Analysts have assigned a consensus price target of 6.00 EUR, with no strong buy or hold recommendations.
- The company's liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
- No revenue concentration or segment-level data is available, limiting the ability to assess geographic or product-line risk.
- The company's profitability and return metrics are not disclosed, making it difficult to compare with industry peers.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue €14.0M, −33,3% YoY; Operating income −59,6% YoY.
- ▍Revenue €14.0M, −33,3% YoY
- ▍Operating income −59,6% YoY
- ▍Net income −36,5% YoY
- ▍Free cash flow +43,0% YoY
- ▍Net margin 5.0%
Revenue €21.0M, −18,9% YoY; Operating income +24,0% YoY.
- ▍Revenue €21.0M, −18,9% YoY
- ▍Operating income +24,0% YoY
- ▍Net income +8,6% YoY
- ▍Free cash flow +211,7% YoY
- ▍Net margin 5.3%
Revenue €25.9M, +8,0% YoY; Operating income +289,3% YoY.
- ▍Revenue €25.9M, +8,0% YoY
- ▍Operating income +289,3% YoY
- ▍Net income +737,2% YoY
- ▍Free cash flow +32,5% YoY
- ▍Net margin 4.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,01 |
| Revenue | —no estimate | —no estimate | 15,6M EUR |
| Operating income | —no estimate | —no estimate | 0 EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Geratherm Medical AG Market data — financials · 2026-05-28
- Geratherm Medical AG Market data — analyst estimates · 2026-05-28
Ownership & reference
Leadership
- Gert Michael FrankChairman of the Supervisory Board